Palisade Bio, Inc.

Sep 21, 2026

▲ +5%today

Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

Palisade Bio, a clinical-stage biopharmaceutical company, will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026. CEO JD Finley and CMO Mitchell Jones will discuss the PALI-2108 clinical development program, focusing on ulcerative colitis and Crohn's disease. The event will also include opportunities for one-on-one meetings with investors.

Sep 3, 2026

Palisade Bio to Participate in Upcoming Investor Conferences

Palisade Bio, Inc. announced its participation in three upcoming healthcare investor conferences in September 2026. The conferences include the Wells Fargo 2026 Healthcare Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the H.C. Wainwright 28th Annual Global Investment Conference. The company is also advancing its lead candidate, PALI-2108, into Phase 2 clinical trials for inflammatory bowel disease.

Aug 10, 2026

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development

Palisade Bio reported its second quarter 2026 financial results, highlighting the advancement of PALI-2108 into Phase 2 trials for ulcerative colitis and Crohn's disease. The company expects to enroll the first patient in the ASCENTRA-UC trial in the latter half of 2026, with primary efficacy results anticipated in 2027. Despite a significant net loss, Palisade's strong financial position supports its clinical development plans.

Jul 10, 2026

Palisade Bio to Participate in the Leerink Partners Therapeutics Forum

Palisade Bio, Inc. will participate in the Leerink Partners Therapeutics Forum on July 14-15, 2026, in Boston. CEO JD Finley and CMO Dr. Mitchell Jones will engage in one-on-one meetings with investors to discuss the clinical development of PALI-2108, a PDE4 inhibitor prodrug. The company is advancing towards Phase 2 studies for inflammatory bowel diseases.

Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis

Palisade Bio has received FDA clearance for its IND application for PALI-2108, allowing the initiation of the ASCENTRA-UC Phase 2 trial in ulcerative colitis. The trial will enroll up to 204 patients across North America and Europe, with results expected in late 2027. This marks a significant milestone for the company's inflammatory bowel disease portfolio.

Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors

Palisade Bio has appointed Robert Baltera and Jordan Zwick to its Board of Directors, enhancing its leadership team with extensive biopharmaceutical expertise. The company is progressing PALI-2108, a PDE4 inhibitor prodrug, toward Phase 2 clinical studies following encouraging results from earlier trials. This strategic move aims to strengthen the company's growth and development in addressing inflammatory bowel diseases.

Jun 9, 2026

Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium

Palisade Bio will present on PALI-2108, a PDE4 inhibitor prodrug, at the NYAS symposium. The presentation will address the unmet needs in treating fibrostenotic Crohn's disease and discuss preclinical findings supporting the drug's potential. PALI-2108 has shown promise in early clinical trials, and the company is moving towards Phase 2 studies.

Jun 9, 2026

Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium

Palisade Bio will present at the NYAS symposium on the potential of PALI-2108 for treating fibrostenotic Crohn's disease. The presentation will cover the unmet medical needs in this area and the scientific rationale behind using a locally bioactivated PDE4 inhibitor. PALI-2108 has shown promise in early clinical trials, advancing towards Phase 2 studies.

May 27, 2026

Palisade Bio to Participate in the Jefferies Global Healthcare Conference

Palisade Bio, Inc. is set to present at the Jefferies Global Healthcare Conference from June 2-4, 2026, with a scheduled presentation on June 4. CEO JD Finley and CMO Dr. Mitchell Jones will lead the discussion, covering the company's innovative oral PDE4 inhibitor, PALI-2108, which shows promise in treating inflammatory and fibrotic diseases. The firm is moving forward to Phase 2 studies after positive outcomes in earlier clinical trials for ulcerative colitis and Crohn’s disease. Management will also hold one-on-one meetings with investors during the conference.

May 13, 2026

Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108

Palisade Bio reported its first quarter 2026 financial results, highlighting the progress of its lead program, PALI-2108, a PDE4 inhibitor prodrug for inflammatory bowel disease. The company plans to initiate Phase 2 trials for ulcerative colitis and Crohn's disease in 2026, supported by a strong financial position. Recent data indicate sustained efficacy and safety of PALI-2108, reinforcing its potential as a treatment option.

May 12, 2026

Palisade Bio, Inc. Condensed Consolidated St ateme nts of Cash Flows (Unaudited) (in thousands) Three Months Ended

Palisade Bio, Inc. reported its first quarter 2026 financial results and highlighted significant progress in its lead program, PALI-2108, a PDE4 inhibitor prodrug aimed at treating inflammatory bowel diseases. Following positive Phase 1 trial data, the company is advancing towards Phase 2 studies for Ulcerative Colitis and Crohn's disease, with expected trial initiations in 2026. Financially, the company maintains a robust balance sheet, allowing it to fund its clinical endeavors through the next crucial milestones.

Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis

Palisade Bio presented additional Phase 1a/b data for PALI-2108, highlighting its potential as a once-daily oral therapy for ulcerative colitis. The findings indicate sustained active metabolite exposure above the IC90 threshold, supporting continuous target inhibition. The data also show significant improvements in clinical and histologic outcomes, reinforcing the drug's localized pharmacologic activity.

Apr 16, 2026

Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026

Palisade Bio announced that its lead program, PALI-2108, will be presented at Digestive Disease Week 2026. The poster presentation will showcase data on the drug's effectiveness in treating ulcerative colitis. The event will take place in Chicago from May 2-5, 2026, where the company will engage with experts and investors.

Apr 8, 2026

Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference

Palisade Bio, Inc. will present at the Needham & Co. 25th Annual Healthcare Conference on April 16, 2026. CEO JD Finley and CMO Dr. Mitchell Jones will discuss the company's advancements in oral PDE4 inhibitor prodrugs. The presentation will be accessible via webcast, and management will hold one-on-one meetings with investors.

Apr 8, 2026

Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference

Palisade Bio, Inc. announced its participation in the Needham & Co. 25th Annual Healthcare Conference, with a presentation scheduled for April 16, 2026. The company will showcase its next-generation oral PDE4 inhibitor prodrugs, including its lead program PALI-2108, which is aimed at treating chronic inflammatory and fibrotic diseases. In addition to the presentation, Palisade management will engage in one-on-one meetings with registered investors, highlighting their commitment to transparency and communication.

Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease

Palisade Bio reported positive topline results from its Phase 1b study of PALI-2108 in patients with fibrostenotic Crohn's disease. The study demonstrated favorable safety and tolerability, with no serious adverse events. Notably, 40% of participants achieved endoscopic response and remission, alongside significant reductions in inflammatory biomarkers. The company plans to advance PALI-2108 into a Phase 2 trial targeting moderate to severe Crohn's disease.

Mar 2, 2026

Palisade Bio Announces Participation in Two Upcoming Investor Conferences

Palisade Bio, Inc. announced its participation in two investor conferences in March 2026, where management will present and hold meetings. The company is advancing its lead program, PALI-2108, which has shown a 100% clinical response in a Phase 1b trial for ulcerative colitis. Palisade is preparing for a Phase 2 study to further evaluate the drug's efficacy and safety.

Feb 23, 2026

Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026

Palisade Bio presented promising Phase 1b data for PALI-2108 at the ECCO 2026 congress. The data revealed rapid clinical responses and significant improvements in inflammatory markers within seven days of treatment. The localized action of the drug in the colon supports its targeted mechanism, with no serious adverse events reported. The company plans to advance PALI-2108 into Phase 2 studies.

Feb 17, 2026

Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

Palisade Bio has appointed Dr. Bram Verstockt to its Clinical Advisory Board, enhancing its expertise in inflammatory bowel disease as it prepares for Phase 2 development of PALI-2108. The company plans to submit an IND application for a Phase 2 study in ulcerative colitis in the first half of 2026. PALI-2108 has shown a 100% clinical response in a Phase 1b trial, indicating strong potential for treating inflammatory bowel diseases.

Feb 9, 2026

Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium

Palisade Bio, Inc. will participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12, 2026. CEO JD Finley and CMO Dr. Mitchell Jones will engage in a fireside chat, discussing the company's innovative PDE4 inhibitor, PALI-2108, which has shown a 100% clinical response in a Phase 1b trial. The company is moving towards a Phase 2 study to further evaluate the drug's efficacy.

Feb 5, 2026

▼ -5.1%on this newsshared move

Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Palisade Bio, Inc. will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. CEO JD Finley and CMO Dr. Mitchell Jones will discuss the company's lead program, PALI-2108, which has shown promising results in a Phase 1b trial for ulcerative colitis. The presentation will be accessible via a live webcast.

Jan 29, 2026

Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

Palisade Bio has appointed renowned IBD experts Laurent Peyrin-Biroulet and David T. Rubin to its Clinical Advisory Board. Their expertise will guide the development of PALI-2108, an oral PDE4 inhibitor prodrug, as it progresses toward Phase 2 trials for ulcerative colitis and fibrostenotic Crohn's disease. The company plans to submit an IND for Phase 2 UC trials in early 2026.

Jan 19, 2026

▲ +13.9%on this news

Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences

Palisade Bio announced that two abstracts on its lead program, PALI-2108, have been selected for poster presentations at prominent inflammatory bowel disease conferences in early 2026. The presentations will focus on the drug's gut-targeted PDE4B inhibition and its Phase 1a findings in ulcerative colitis. The company aims to engage with the global IBD community to discuss these promising results.

Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108

Palisade Bio announced a strategic equity investment of up to $500,000 from the Crohn's & Colitis Foundation's IBD Ventures program to support the development of PALI-2108. This PDE4 inhibitor targets ulcerative colitis and fibrostenotic Crohn's disease, addressing significant unmet needs. The investment underscores the potential of PALI-2108, which has shown promising results in early clinical trials.

Jan 7, 2026

▲ +5.2%on this newsshared move

Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108

Palisade Bio announced a strategic equity investment of up to $500,000 from the Crohn’s & Colitis Foundation to advance PALI-2108, a PDE4 inhibitor targeting ulcerative colitis and fibrostenotic Crohn’s disease. The investment supports ongoing clinical studies, with promising results reported in earlier phases. PALI-2108 aims to address significant unmet needs in these conditions.

Dec 30, 2025

PALIFDA Updates

Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108

Palisade Bio has received a Japanese patent for PALI-2108, a PDE4 inhibitor aimed at treating ulcerative colitis and fibrostenotic Crohn's disease. This patent, which extends into 2041, enhances the company's intellectual property for its innovative drug. PALI-2108 has completed Phase 1 studies and is set for Phase 2 IND submission in early 2026.

Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

Palisade Bio has appointed Dr. James Izanec as Vice President of Clinical Development. Dr. Izanec, a seasoned gastroenterologist, brings over 20 years of experience in clinical trials, particularly in immunology and gastroenterology. His leadership is expected to significantly impact the development of PALI-2108, a promising treatment for ulcerative colitis and Crohn's disease. The company is preparing for a Phase 2 clinical study.

Nov 25, 2025

▼ -5.7%on this news· ran to -18% by day 3

Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference

Palisade Bio, Inc. announced their participation in the Piper Sandler 37th Annual Healthcare Conference, featuring a live webcast fireside chat with CEO JD Finley and CMO Dr. Mitchell Jones. The company is focusing on advancing PALI-2108, a new oral PDE4 inhibitor prodrug aimed at treating inflammatory and fibrotic diseases, particularly moderate-to-severe Ulcerative Colitis and Fibrostenotic Crohn’s Disease. Recent Phase 1b trial results showed encouraging outcomes for PALI-2108, prompting preparations for a Phase 2 clinical study to assess its effectiveness and safety further.

Oct 28, 2025

▲ +11.4%on this news· ran to +28% by day 1

Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations

Palisade Bio has appointed Sharon Skare as Vice President, Global Head of Clinical Operations. With over 24 years of experience, she will lead the advancement of PALI-2108, a therapy targeting ulcerative colitis and Crohn's disease. The company plans to submit an IND for Phase 2 studies in the first half of 2026, building on positive Phase 1 data.

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)

Palisade Bio has initiated dosing for the first patients in its Phase 1b study of PALI-2108, a novel PDE4 inhibitor prodrug aimed at treating fibrostenotic Crohn's disease. This study is significant as it targets a condition with no approved therapies. Topline safety and pharmacokinetic data are expected in Q1 2026, with plans for a Phase 2 IND submission in H1 2026.

Oct 20, 2025

▲ +6.9%on this newsshared move

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)

Palisade Bio has initiated dosing of the first patients in its Phase 1b study for PALI-2108, a novel PDE4 inhibitor prodrug aimed at treating fibrostenotic Crohn's disease. This study will assess the drug's safety, pharmacokinetics, and pharmacodynamics. Topline results are anticipated by Q1 2026, with further development planned for ulcerative colitis.

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

Palisade Bio has received a Canadian patent for its lead product candidate PALI-2108, a PDE4 inhibitor aimed at treating fibrostenotic Crohn's disease and ulcerative colitis. The patent secures composition-of-matter protection until May 2041. The company is progressing with clinical trials, with patient dosing for a Phase 1b study expected in late 2025.

Oct 9, 2025

Palisade Bio Announces Cancellation of Special Meeting of Stockholders

Palisade Bio has canceled its special meeting of stockholders originally scheduled for October 10, 2025, due to insufficient proxies to meet quorum requirements. This meeting was previously adjourned without any business conducted. The company will withdraw the proposals outlined in its proxy statement filed on August 18, 2025.

▼ -5.9%on this news· ran to +18% by day 3

Oct 2, 2025

PALIFDA Updates

Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option

Palisade Bio has successfully closed a $138 million public offering, including the full exercise of the over-allotment option. The proceeds will be utilized to advance the Phase 2 clinical development of PALI-2108, a novel treatment for ulcerative colitis. The offering was well-received, reflecting investor confidence in the company's potential.

Oct 1, 2025

▲ +52.4%on this news· ran to +122% by day 3shared move

Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock

Palisade Bio has announced the pricing of an upsized underwritten public offering of 171,440,559 shares at $0.70 per share, aiming to raise approximately $120 million. The offering is expected to close around October 2, 2025, pending customary closing conditions. Ladenburg Thalmann & Co. Inc. is managing the offering, which includes an option for underwriters to purchase additional shares.

Sep 26, 2025

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

Palisade Bio announced the adjournment of its special meeting of stockholders due to insufficient quorum, as less than one-third of the outstanding shares were present. The meeting will reconvene on October 10, 2025, allowing more time for stockholders to vote on proposals. The company continues to solicit votes and has engaged a proxy solicitor to assist in achieving the required quorum.

Sep 17, 2025

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

Palisade Bio reported positive Phase 1b clinical data for PALI-2108, showing a 100% clinical response in ulcerative colitis patients without serious adverse events. The study indicated strong safety and promising efficacy signals, with biomarker analyses supporting its potential in treating fibrotic conditions. Patient dosing for the Phase 1b study in fibrostenotic Crohn's disease is expected to begin in 2025.

Sep 5, 2025

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)

Palisade Bio has received Health Canada clearance for a Phase 1b trial of PALI-2108, a novel treatment for fibrostenotic Crohn's disease. This first dual-acting anti-inflammatory and anti-fibrotic candidate aims to address a significant unmet need, as current therapies do not effectively alter the disease process. Patient dosing is expected to start in H2 2025, with topline data anticipated in Q1 2026.

Sep 5, 2025

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)

Palisade Bio has received Health Canada clearance for a Phase 1b trial of PALI-2108, a dual-acting anti-inflammatory and anti-fibrotic therapy for fibrostenotic Crohn's disease (FSCD). The trial will begin patient dosing in H2 2025, with topline data expected in Q1 2026. This marks a significant milestone as there are currently no approved therapies for FSCD.

Aug 25, 2025